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Abstract: Von Willebrand disease, the most common hereditary bleeding disorder, arises 
from quantitative or qualitative defect of von Willebrand factor (VWF). The aim of the treat-
ment is to correct the dual defect of hemostasis caused by the abnormal/reduced VWF and the 
concomitant deﬁ  ciency of factor VIII (FVIII). The synthetic vasopressin analogue desmopressin 
is the mainstay of therapy in about 80% of patients, while nearly 20% are unresponsive and 
must be treated with FVIII/VWF concentrates. This latter therapeutic option will be focused in 
the review, with particular consideration to the management of surgery and invasive procedures 
in these patients.
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Introduction
Von Willebrand disease (VWD) is the most common genetic bleeding disorder with 
a prevalence of approximately 1%–2% conﬁ  rmed in different population studies 
(Rodeghiero et al 1987). The severity of the bleeding tendency is usually proportional 
to the degree of the VWF defect, although the large majority of cases diagnosed appear 
to have a mild disease (Castaman et al 2003).
In this review, we summarize the most important clinical, diagnostic, laboratory 
and therapeutic features of VWD. In particular, we focus on the use of factor VIII 
(FVIII)/von Willebrand factor (VWF) concentrates for the management of surgical 
or other invasive procedures in VWD patients.
Structure and function of von Willebrand factor
VWF is synthesized by endothelial cells and megakaryocytes. The gene coding for 
VWF has been cloned and located at chromosome 12p13.2. It is a large gene com-
posed of about 178 kilobases and containing 52 exons. The primary product of the 
VWF gene is a 2813 amino acid protein made of a signal peptide of 22 amino acids 
(also called pre-peptide), a large pro-peptide of 741 amino acids and a mature VWF 
molecule containing 2050 amino acids. Different protein regions, corresponding 
to four types of repeated domains (D1, D2, D’, D3, A1, A2, A3, D4, B, C1, C2) of 
cDNA, are responsible for the different binding functions of the molecule. VWF is 
the result of ordered intra-cellular processing, leading to the storage and/or secretion 
of a heterogeneous array of multimeric multi-domain glycoproteins, referred to as 
VWF (Ruggeri 2001).
VWF has two major functions in hemostasis. First, it is essential for platelet-
subendothelium adhesion and platelet-to-platelet interactions as well as platelet Biologics: Targets & Therapy 2007:1(3) 286
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aggregation in vessels in which rapid blood ﬂ  ow results in 
elevated shear stress. Adhesion is promoted by the interaction 
of a region of the A1 domain of VWF with GpIbα on platelet 
membrane. It is thought that high shear stress activates the A1 
domain of the collagen-bound VWF by stretching VWF mul-
timers into their ﬁ  lamentous form. Furthermore GPIbα and 
VWF are also necessary for platelet-to-platelet interactions. 
Aggregation of platelets within the growing haemostatic 
plug is promoted by the interaction with a second receptor 
on platelets, GPIIb-IIIa which, once activated, binds to VWF 
and ﬁ  brinogen, recruiting more platelets into a stable plug. 
Both these binding activities of VWF are highly expressed 
in the largest VWF multimers (Ruggeri 2001).
Second, VWF is the speciﬁ  c carrier of FVIII in plasma. 
VWF protects FVIII from proteolytic degradation, prolong-
ing its half-life in circulation and efﬁ  ciently localizing it at the 
site of vascular injury. Each VWF monomer has one binding 
domain, located in the ﬁ  rst 272 amino acids of the mature 
subunit (D’ domain) which can bind one FVIII molecule; 
in vivo, however only 1%–2% of available monomers are 
occupied by FVIII. Therefore, any change in plasma VWF 
level is usually associated with a concordant change in FVIII 
plasma concentration (Vlot et al 1998).
Classiﬁ  cation and diagnosis
of von Willebrand disease
Inherited VWD has been subdivided in three types (Franchini 
et al 2007). Type 1 and 3 VWD reﬂ  ect, respectively, the 
partial or virtually complete deﬁ  ciency of VWF while type 
2 VWD reﬂ  ects a qualitative deﬁ  ciency of VWF. Type 1 is 
the most common form of VWD, accounting for approxi-
mately 80% of all cases, and is transmitted as an autosomal 
dominant trait with incomplete penetrance. Type 1 disease 
is characterized by a mild to moderate reduction in von 
Willebrand factor antigen (VWF:Ag) and ristocetin cofactor 
(VWF:RCo) plasma levels. The VWF is functionally 
normal, as is the range of plasma VWF multimers, and the 
plasma level of factor VIII (FVIII) is reduced in proportion 
to the VWF level. These patients manifest a spectrum of 
mucocutaneous bleeding symptoms, the severity of which 
usually correlates with the level of their VWF deﬁ  ciency 
(Federici 2004).
Type 2 VWD is divided in four subtypes: type 2A, 2B, 
2M and 2N. Type 2A von Willebrand disease is the most 
frequent subtype among type 2 VWD. It is inherited mainly 
with an autosomal dominant pattern, but a recessive modality 
of transmission is also described. The hallmark of type 2A 
disease is a low VWF:RCo to VWF:Ag ratio (0.7), with 
absent high molecular weight VWF multimers and impaired 
ristocetin-induced platelet agglutination (RIPA). Like type 
2A, the inheritance pattern of type 2B is mainly autosomal 
dominant, but cases with apparently recessive patterns have 
also been described. Typical laboratory characteristics of 
type 2B include a mild thrombocytopenia, low to normal 
FVIII, low to normal VWF:Ag, low VWF:RCo, heightened 
RIPA and absence of large multimers from plasma. Type 
2M VWD disease includes variants in which binding to 
platelets is impaired but the VWF multimeric distribution is 
normal. Laboratory results generally are similar to those in 
type 2A, but there is the presence of a normal plasma mul-
timeric pattern. Finally, type 2N von Willebrand disease is 
characterized by normal levels of VWF:Ag and VWF:RCo 
and normal multimeric structure, but low plasma FVIII levels 
due to the decreased plasma half-life of FVIII, which cannot 
bind to VWF as a consequence of an intrinsic abnormal-
ity of VWF. It therefore resembles haemophilia A, but its 
inheritance pattern is not X-linked but autosomal recessive 
(Laffan et al 2004).
Type 3 VWD is inherited by an autosomal recessive trait 
and is characterized by undetectable levels of VWF in plasma 
and platelets and by very low plasma levels (1%–5%) of FVIII. 
As a consequence, patients with type 3 VWD experience a 
severe bleeding tendency characterized not only by mucocu-
taneous hemorrhages but also by hemarthroses and hematomas 
as observed in severe hemophilia (Federici et al 2002).
The classiﬁ  cation of VWD is reported in Table 1.
Treatment of von Willebrand 
disease
The aim of therapy for VWD is correct the dual defect of 
hemostasis, ie, the abnormal platelet adhesion and the abnor-
mal coagulation due to low FVIII levels (Mannucci 2001). 
There are two treatments of choice in VWD, ie, desmopres-
sin (DDAVP) and transfusional therapy with blood products 
(Mannucci 2004). Other non-transfusional therapies, like 
antiﬁ  brinolytic agents, have been successfully used alone 
or in association with standard treatment for patients with 
VWD, particularly for oral and other moderate mucous 
membrane bleeding.
DDAVP is most effective in patients with type 1 VWD. 
In these patients FVIII, VWF and BT are usually corrected 
within 30 min after administration and remain normal for 6–8 h. 
However, most patients initially responsive to DDAVP, 
become less responsive to therapy when treated repeatedly 
(phenomenon called tachyphylaxis). In other VWD subtypes, 
responsiveness to DDAVP is variable. In type 2A, FVIII Biologics: Targets & Therapy 2007:1(3) 287
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levels are usually increased by DDAVP but BT is shortened 
in only a minority of cases. DDAVP is contraindicated in 
type 2B because of the transient appearance of thrombocy-
topenia. Type 2M shows a variable pattern of response and 
the decision to use desmopressin should be made based on 
the results of a test infusion. In type 2N, relatively high levels 
of FVIII are observed following DDAVP, but released FVIII 
circulates for a shorter time period in patient plasma because 
the stabilizing effect of VWF is impaired. Finally, patients 
with type 3 VWD are usually unresponsive to DDAVP 
(Mannucci 2000).
For those VWD patients in whom DDAVP is either 
ineffective or contraindicated, VWF and FVIII levels can be 
restored by the infusion of virus-inactivaed plasma-derived 
concentrates of these proteins. Several intermediate and 
high-purity FVIII-VWF products are commercially available 
(see Table 2) and many reports in the literature have docu-
mented their efﬁ  cacy in the treatment of bleeding episodes 
or as prophylaxis of hemorrhages during surgical or invasive 
procedures in VWD patients.
A retrospective survey on the use of Haemate P reported 
97 patients with all types of VWD who were treated for 
73 surgical operations, 344 bleeding events and 93 other 
events including invasive procedures. The efﬁ  cacy was rated 
as excellent or good in 99% of surgical operations, 97% of 
bleeding episodes and 86% of other events (Dobrkovska 
et al 1998). The same intermediate-purity FVIII/VWF con-
centrate was utilized in a large retrospective study organized 
by the Canadian Hemophilia Centers. Patients were treated 
for 437 events, including bleeding episodes and surgical 
procedures. The rates of excellent-to-good responses were 
97% overall, 99% in surgical procedures, 97% in bleeding 
episodes and 86% in other cases (Lillicrap et al 2002). Other 
two prospective studies supported the safety and efﬁ  cacy of 
Hemate P for the treatment of urgent bleeding and urgent 
surgical events (Gill JC et al 2003; Thompson et al 2004). 
We have previously reported the experience of three Italian 
hemophilia centers on 26 VWD patients who underwent 
43 surgical or invasive procedures (14 major surgery, 
11 minor surgery, 11 dental extractions and 7 invasive 
diagnostic procedures) under coverage with Haemate P 
(Franchini et al 2003). The mean daily dose of concentrate 
given was 39.3 (range 25–52.5) IU VWF:RCo/kg for major 
surgery, 28.7 (range 21.4–34.8) IU VWF:RCo/kg for minor 
Table 1 Classiﬁ  cation of von Willebrand disease
VWD type  Transmission  Pathogenic mechanism  Laboratory parameters
      VWF:Ag VWF:RCo  FVIII:C  VWF:RCo/ RIPA Multimers
           VWF:Ag   
Type 1  AD  Partial quantitative deﬁ  ciency   ↓  ↓ N/↓  0.7  ↓ Uniform  ↓ of all
   of  VWF           multimers
Type 2  AD, AR  Qualitative defects of VWF
2A   Decreased  platelet-dependent  ↓↓  ↓ N/↓  0.7  ↓  Lack of HMWM
   VWF  function
2B   Increased  platelet-dependent  ↓↓  ↓ N/↓  0.7  ↑  Lack of HMWM
   VWF  function
2M   Decreased  platelet-dependent  ↓  ↓ N/↓  0.7  ↓ Normal  or
   VWF  function           supranormal
2N   Decreased  VWF  afﬁ  nity for FVIII  N  N  ↓  0.7 N  Normal
Type 3  AR  Complete deﬁ  ciency of VWF  ↓↓↓  ↓↓↓ ↓↓↓ –  ↓↓↓ Undetectable
Abbreviations: N, normal; AD, autosomal dominant; AR, autosomal recessive; FVIII, factor VIII; FVIII:C, factor VIII coagulant; GP, glycoprotein; HMWM, high molecular weight 
multimers; RIPA, ristocetin-induced platelet agglutination; VWD, von Willebrand disease; VWF, von Willebrand factor; VWF:Ag, von Willebrand factor antigen; 
VWF:RCo, von Willebrand factor ristocetin cofactor.
Table 2 FVIII/VWF concentrates registered in Italy for the treatment of von Willebrand disease
Product Manufacturer  Puriﬁ  cation  Viral inactivation  FVIII activity  VWF:RCo/FVIII
       (U/mg  protein)  (ratio)
Alphanate Grifols  Afﬁ  nity chromatography  S/D + 72 h at 80 °C  100 1.6
Fanhdi Grifols  Afﬁ  nity chromatography  S/D + 72 h at 80 °C  100 1.6
Haemate P  CSL Behring  Multiple precipitation  Pasteurization 10 h at 60 °C 40  ± 6 2.5
Immunate  Baxter  Ion exchange chromatography  D/VH 10 h at 60 °C + 1 h at 80 °C 100  ± 50 1.1
Abbreviations: VWF, von Willebrand factor; RCo, ristocetin cofactor; Ag, antigen; FVIII, factor VIII; S/D, solvent/detergent; D/VH, detergent/vapor heat.Biologics: Targets & Therapy 2007:1(3) 288
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surgery, 24.0 (range 23.5–25) IU VWF:RCo/kg for dental 
extractions and 32.3 (range 27.3–37) IU VWF:RCo/kg for 
invasive procedures. The mean days of treatment were 9.7 
(range 5–23) for major surgery, 4.2 (range 2–7) for minor 
surgery, 1.6 (range 1–5) for dental extractions and 2.7 (range 
1–5) for invasive procedures. As only a bleeding episode 
was recorded without drug-related adverse events, we con-
cluded that Haemate P was safe and effective in preventing 
excessive bleeding after major and minor surgery or invasive 
procedures in VWD patients.
An Italian retrospective multicenter cohort study 
(Federici et al 2007) evaluated the response to Haemate 
P in 100 VWD patients treated for bleeding, surgeries or 
prophylaxis and recorded a 97% of excellent/good clinical 
response in the 56 patients who underwent 73 surgical or 
invasive procedures. Finally, a prospective multicenter 
trial on 29 subjects with VWD undergoing elective sur-
gery found that Haemate P, whose preoperative loading 
dose was based on a pharmacokinetic study, provided an 
excellent or good hemostasis in 96.3% of subjects on the 
day of surgery and 100% on the next days (Lethagen et al 
2007).
The highly puriﬁ  ed, doubly virus-inactivated FVIII/VWF 
concentrate Fanhdi has been reported to be efﬁ  cacious in the 
management of VWD in a retrospective clinical study (Federici 
et al 2002). In 22 patients 12 bleeding episodes and invasive 
procedures were treated with Fanhdi. There was 92% excellent 
or good efﬁ  cacy and no adverse events.
The results of a large international prospective study 
by the Alphanate study Group were published in 2002 and 
included 39 patients receiving prophylactic treatment for 
71 surgical or invasive diagnostic procedures. A good clinical 
response with this FVIII/VWF concentrate was observed in 
71% of patients (Mannucci et al 2002). It was also demon-
strated that surgery could be safely undertaken even when 
Alphanate did not correct the bleeding time.
Goudemand and colleagues (Goudemand et al 1998) 
reported the French clinical experience on the use of the 
very high purity VHP VWF concentrate in 75 VWD patients 
treated on 99 occasions either to control spontaneous bleed-
ing or to prevent hemorrhagic risk associated with surgery. 
Successful treatment of 31 minor and 23 major surgical 
procedures was reported.
Finally a single center ten year retrospective review 
conducted in United Kingdom identiﬁ  ed 38 patients who 
received various FVIII/VWF concentrates for 68 elective 
surgical events (Nitu-Whalley et al 2001). The effectiveness 
of hemostasis was judged excellent in 56 (82%) surgical 
events. Table 3 summarizes the literature results.
On the whole, the literature results document that 20–50 
IU/kg of FVIII/VWF concentrates given once daily until heal-
ing is complete are hemostatically effective in preventing bleed-
ing in the majority of surgical or invasive procedures. Thus, for 
major procedures, FVIII and VWF:RCo levels should be raised 
to 80–100 UI/dL at the time of surgery and maintained above 
50 IU/dL for at least 7–14 days. For minor procedures, FVIII 
Table 3 Literature results on the use of FVIII/VWF during surgical or invasive procedures
Author, year  Product  Pts  VWD types  Type of interventions  Dose range  Efﬁ  cacy (%)
Nitu-Whalley, 2001  Haemate   38  26 type 1, 6 type 2,  10 major, 35 minor,   14–77 IU FVIII:C/kg/d  82
  P/BPL 8Y    3 type 3  18 oral surgeries
Lillicrap, 2002  Haemate P  73  26 type 1, 20 type 2,   73 surgery  11.9–222.8 IU VWF:
      21 type 3, 6 NI    RCo/kg  99
Franchini, 2003  Haemate P  26  19 type 1, 7 type 2  14 major, 11 minor,   21.4–52.5 IU VWF:
        11 oral surgeries, 7 IP  RCo/kg/d  98
Thompson, 2004  Haemate P  39  16 type 1, 9 type 2,   25 major, 17 minor surgeries  32.5–216.8 IU VWF:
      8 type 3, 6 NI    RCo/kg  100
Federici, 2007  Haemate P  56  19 type 1,   17 major, 28 minor,   27–146 IU VWF:
      27 type 2, 10 type 3  19 oral surgeries, 9 IP  RCo/kg/d  97
Lethagen, 2007  Haemate P  29  10 type 1, 11 type 2,  16 major, 11 minor  50.1–87.0 IU VWF:
      8 type 3    RCo/kg  96.3
Federici, 2002  Fanhdi  14  5 type 1, 7 type 2,  7 major, 5 minor,   17–92 IU FVIII:C/kg/d  93
      2 type 3  2 oral surgeries
Mannucci, 2002  Alphanate  39  6 type 1, 19 type 2,  71 surgical or invasive   20–76 IU VWF:
      14 type 3  procedures  RCo/kg  96
Goudemand, 1998  VHP  54  NI  23 major, 31 minor surgeries  51–55 IU VWF:RCo/kg  100
Borel-Derlon, 2007  Wilfactin  44  5 type 1, 25 type 2,  43 major or minor,   11.1–100 IU VWF:RCo/kg  100
      14 type 3  14 oral surgeries, 51 IP
Abbreviations: Pts, patients; VWD, von Willebrand disease; VWF, von Willebrand factor; FVIII:C, factor VIII coagulant activity; NI, not indicated; VWF:RCo, von Willebrand 
factor ristocetin cofactor; IP, invasive procedures; d, day.Biologics: Targets & Therapy 2007:1(3) 289
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and VWF:RCo levels above 50 IU/dL at the time of surgery 
are advisable, followed by levels above 30 IU/dL for at least 
5–7 days. Finally, dental extractions or invasive procedures 
may be managed with a single concentrate infusion aimed to 
reach VWF:RCo/FVIII levels of about 50 IU/dL.
However, the accumulation of FVIII that is exogenously 
infused together with that endogenously synthesized and 
stabilized by the infused VWF may result in very high FVIII 
concentrations (150 IU/dL) when several infusions are given 
for severe bleeding episodes or to cover major surgery. There is 
some concern that sustained high concentrations of FVIII may 
increase the risk of postoperative deep vein thrombosis, as sug-
gested by recent observations (Kyrle et al 2000). Therefore we 
suggest, when repeated injections of FVIII/VWF concentrates 
are administered, to monitor daily FVIII plasma levels.
Some authors have proposed the use of VWF:RCo units 
to calculate the dose of FVIII/VWF concentrate to adminis-
ter and to monitor the response to treatment. Although this 
practice would better tailor the therapy of VWD patients 
avoiding the high post-infusion FVIII levels, it is not stan-
dardized and validated by prospective studies. Moreover, 
this test can be performed only by specialized coagulation 
laboratories (Ewenstein 2001).
In order to avoid high post-infusion FVIII plasma lev-
els, a high-purity VWF concentrate with low FVIII content 
(Wilfactin, LFB) has been recently developed and its efﬁ  cacy 
tested in a prospective study on 50 VWD patients (Borel-
Derlon et al 2007). The hemostatic outcome was judged 
excellent or good in all the 108 surgical or invasive proce-
dures performed and no adverse thrombotic complications 
were recorded.
Conclusions
FVIII/VWF concentrates play a valuable role in the manage-
ment of patients with VWD who are unresponsive to DDAVP. 
Literature data testify that these products have an excellent 
level of safety and efﬁ  cacy. However, further clinical trials are 
needed to improve the dosing and monitoring of these products 
in VWD patients during surgical or invasive procedures.
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